- Home
- ARAY vs ELDN Comparison
ARAY vs ELDN Comparison
Compare ARAY & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARAY
- ELDN
- Stock Information
- Founded
- ARAY 1990
- ELDN 2004
- Country
- ARAY United States
- ELDN United States
- Employees
- ARAY N/A
- ELDN N/A
- Industry
- ARAY Medical/Dental Instruments
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- ARAY Health Care
- ELDN Health Care
- Exchange
- ARAY Nasdaq
- ELDN Nasdaq
- Market Cap
- ARAY 171.0M
- ELDN 140.3M
- IPO Year
- ARAY 2007
- ELDN N/A
- Fundamental
- Price
- ARAY $1.70
- ELDN $4.00
- Analyst Decision
- ARAY Strong Buy
- ELDN Strong Buy
- Analyst Count
- ARAY 1
- ELDN 1
- Target Price
- ARAY $9.00
- ELDN $16.00
- AVG Volume (30 Days)
- ARAY 646.4K
- ELDN 985.1K
- Earning Date
- ARAY 11-06-2024
- ELDN 11-12-2024
- Dividend Yield
- ARAY N/A
- ELDN N/A
- EPS Growth
- ARAY N/A
- ELDN N/A
- EPS
- ARAY N/A
- ELDN N/A
- Revenue
- ARAY $444,204,000.00
- ELDN N/A
- Revenue This Year
- ARAY $6.33
- ELDN N/A
- Revenue Next Year
- ARAY $5.60
- ELDN N/A
- P/E Ratio
- ARAY N/A
- ELDN N/A
- Revenue Growth
- ARAY N/A
- ELDN N/A
- 52 Week Low
- ARAY $1.40
- ELDN $1.11
- 52 Week High
- ARAY $3.05
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- ARAY 40.89
- ELDN 49.97
- Support Level
- ARAY $1.81
- ELDN $4.74
- Resistance Level
- ARAY $2.15
- ELDN $5.40
- Average True Range (ATR)
- ARAY 0.13
- ELDN 0.53
- MACD
- ARAY -0.02
- ELDN -0.11
- Stochastic Oscillator
- ARAY 0.00
- ELDN 24.51
About ARAY Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.